+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Immune Checkpoint Inhibitors Market 2019-2023 - Product Image

Global Immune Checkpoint Inhibitors Market 2019-2023

  • ID: 4704202
  • Report
  • November 2018
  • Region: Global
  • 116 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Pfizer
  • MORE
The growing number of cancer cases being diagnosed across the globe. Various international and national level campaigns are conducted to increase the awareness about cancer and to help early detection of the disease. The analysts have predicted that the immune checkpoint inhibitors market will register a CAGR of almost 3% by 2023.

Market Overview

High target affinity and specificity of immune checkpoint inhibitors drugs

Most of the approved therapies for cancer treatment have severe side effects, which lowers the patient compliance towards the treatment. Thus, these drawbacks help the immune checkpoint inhibitors market grow.

High costs associated with the treatment

Treatment cost is one of the major challenges for cancer patients. The high cost is mainly due to hospitalization, laboratory costs, and novel immunotherapies.

For the detailed list of factors that will drive and challenge the growth of the immune checkpoint inhibitors market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including AstraZeneca and Bristol-Myers Squibb the competitive environment is quite intense. Factors such as the high target affinity and specificity of immune checkpoint inhibitors drugs and the growing number of cancer cases being diagnosed across the globe will provide considerable growth opportunities to immune checkpoint inhibitors manufactures. AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and F. Hoffmann-La Roche are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.’
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • PD-1 inhibitors - Market size and forecast 2018-2023
  • CTLA-4 inhibitors - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Pfizer
PART 14: APPENDIX
  • List of Abbreviations
List of Exhibits
Exhibit 01: Global oncology drugs market
Exhibit 02: Segments of global oncology drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ billions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: PD-1 inhibitors - Market size and forecast 2018-2023 ($ billions)
Exhibit 20: PD-1 inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 21: CTLA-4 inhibitors - Market size and forecast 2018-2023 ($ billions)
Exhibit 22: CTLA-4 inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 23: Others - Market size and forecast 2018-2023 ($ billions)
Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: Americas - Market size and forecast 2018-2023 ($ billions)
Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: EMEA - Market size and forecast 2018-2023 ($ billions)
Exhibit 33: Patient assistance program by AstraZeneca
Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC - Market size and forecast 2018-2023 ($ billions)
Exhibit 37: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Patient assistance programs
Exhibit 42: Combined action of PD-1 and CTLA-4 checkpoint inhibitors
Exhibit 43: Treatment costs of immune checkpoint inhibitor therapeutics in US
Exhibit 44: Side effects of immune checkpoint inhibitors
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Some of the strategic alliances in global immune checkpoint inhibitors market
Exhibit 47: Approved drugs with respect to their cancer indications
Exhibit 48: Expansion of research areas of approved drugs
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: AstraZeneca - Vendor overview
Exhibit 55: AstraZeneca - Business segments
Exhibit 56: AstraZeneca - Organizational developments
Exhibit 57: AstraZeneca - Geographic focus
Exhibit 58: AstraZeneca - Segment focus
Exhibit 59: AstraZeneca - Key offerings
Exhibit 60: AstraZeneca - Key customers
Exhibit 61: Bristol-Myers Squibb - Vendor overview
Exhibit 62: Bristol-Myers Squibb - Business segments
Exhibit 63: Bristol-Myers Squibb - Organizational developments
Exhibit 64: Bristol-Myers Squibb - Geographic focus
Exhibit 65: Bristol-Myers Squibb - Key offerings
Exhibit 66: Bristol-Myers Squibb - Key customers
Exhibit 67: F. Hoffmann-La Roche - Vendor overview
Exhibit 68: F. Hoffmann-La Roche - Business segments
Exhibit 69: F. Hoffmann-La Roche - Organizational developments
Exhibit 70: F. Hoffmann-La Roche - Geographic focus
Exhibit 71: F. Hoffmann-La Roche - Segment focus
Exhibit 72: F. Hoffmann-La Roche - Key offerings
Exhibit 73: F. Hoffmann-La Roche - Key customers
Exhibit 74: Merck Sharp & Dohme - Vendor overview
Exhibit 75: Merck Sharp & Dohme - Business segments
Exhibit 76: Merck Sharp & Dohme - Organizational developments
Exhibit 77: Merck Sharp & Dohme - Geographic focus
Exhibit 78: Merck Sharp & Dohme - Segment focus
Exhibit 79: Merck Sharp & Dohme - Key offerings
Exhibit 80: Merck Sharp & Dohme - Key customers
Exhibit 81: Pfizer - Vendor overview
Exhibit 82: Pfizer - Business segments
Exhibit 83: Pfizer - Organizational developments
Exhibit 84: Pfizer - Geographic focus
Exhibit 85: Pfizer - Segment focus
Exhibit 86: Pfizer - Key offerings
Exhibit 87: Pfizer - Key customers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Pfizer
  • MORE
Global Immune Checkpoint Inhibitors Market 2019-2023

The author of the report recognizes the following companies as the key players in the global immune checkpoint inhibitors market: AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and F. Hoffmann-La Roche.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the growing number of cancer cases being diagnosed across the globe.”

According to the report, one of the major drivers for this market is the high target affinity and specificity of immune checkpoint inhibitors drugs.

Further, the report states that one of the major factors hindering the growth of this market is the high costs associated with the treatment.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Pfizer
Note: Product cover images may vary from those shown
Adroll
adroll